Acorda Therapeutics explores sale: Wall Street Journal

Acorda Therapeutics Inc, a biotech company, is exploring a potential sale, the Wall Street Journal reported. It has hired investment banks Centerview Partners and MTS Health Partners, the story said. Proceedings are at an early stage; Acorda has a market value of $970 million, the WSJ said. Acorda’s main product is the multiple-sclerosis drug Ampyra.